BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

International Journal of Biological and Medical Research (IJBMR)

Original Article
Year : 2026  |  Volume : 17  |  Issue : 4  |  Page : 8842-8847 Full Version
Comparative evaluation of oxymetazoline, xylometazoline, and placebo nasal sprays on odorspecific olfactory perception and cognitive function in healthy adults a randomized doubleblind placebo-controlled crossover pilot study
Int J Biol Med Res. 2026; 17(4): 8842-8847  |  DOI: 10.65048/ijbmr.2026.17.4.8842.1099
Charumathi P. C¹, Priyanka S.²
¹Postgraduate Resident, Department of Pharmacology, Kempegowda Institute of Medical Sciences, Bengaluru, India
²Associate Professor, Department of Pharmacology, Kempegowda Institute of Medical Sciences, Bengaluru, India
Correspondence Address :
Dr. Charumathi P C,
Postgraduate resident (MD Pharmacology),
Department of Pharmacology,
Kempegowda Institute of Medical Sciences, Bengaluru E-mail: charumathipc2000@gmail.com
Received: May 30, 2026 Accepted: July 28, 2026 Published: October 3, 2026

Abstract
Background: Intranasal decongestants such as oxymetazoline and xylometazoline are topical ?-adrenergic agonists widely used for nasal obstruction. Their short-term effects on olfactory perception and cognitive performance remain incompletely understood. Aim: To compare the acute effects of oxymetazoline, xylometazoline, and placebo nasal sprays on olfactory perception, short-term cognitive performance, and subjective nasal patency in healthy adults. Methods: In this randomized, double-blind, placebo-controlled, three-arm crossover pilot study, 24 healthy normosmic adults (18-35 years) received oxymetazoline 0.05%, xylometazoline 0.1%, and placebo (0.9% saline) in a Latin-square sequence with 48-hour washout periods. Olfactory perception (modified 5-item odor identification test and odor intensity visual analogue scale [VAS]), cognitive performance (5-word recall and Stroop test), and nasal patency (VAS) were assessed at baseline and 10, 30, and 60 minutes post-administration. Data were analyzed using repeated-measures ANOVA with Bonferroni correction.[KIMS/IEC/A320/M/2025, CTRI/2025/07/091690]. Results: All 24 participants (mean age 26.5±5.0 years; 50% female) completed the study. Odor identification scores did not differ significantly between treatments at any time point (all p>0.05). Odor intensity ratings were significantly lower with xylometazoline, with the greatest reduction observed at 30 minutes compared with oxymetazoline and placebo (p = 0.001). Both active treatments demonstrated higher 5-word recall scores than placebo at 10 minutes (p<0.001), although these differences were not sustained at later assessments. Stroop test performance did not differ significantly between treatments (all p>0.05). Subjective nasal patency improved significantly with both active treatments compared with placebo (all p<0.001), with earlier improvement observed with xylometazoline and greater improvement at 30 minutes with oxymetazoline. No significant carryover effects or clinically significant adverse events were observed. Conclusion: Oxymetazoline and xylometazoline significantly improved subjective nasal patency without affecting odor identification or attention. Xylometazoline reduced perceived odor intensity, and both agents were associated with transiently higher early recall scores. These findings suggest subtle time-dependent sensory and cognitive effects that warrant confirmation in larger studies.
Keywords
Oxymetazoline, Xylometazoline, Smell, Cognition, Attention

References

[1] Fageeh YA, Basurrah MA, Alazwari KD, Alamri MA, Aljuaid WM, Alhumaidi AA, Alfaqih MH, Alalyani OM. Prevalence of nasal obstruction and its impact on quality of life in Saudi Arabia. J Family Med Prim Care. 2024;13(2):572–578.
[2] Värendh, M., Andersson, M., Bjornsdottir, E., Hrubos-Strøm, H., Johannisson, A., Arnardóttir, E., Gislason, T., & Júlíusson, S. (2018). Nocturnal nasal obstruction is frequent and reduces sleep quality in patients with obstructive sleep apnea. Journal of Sleep Research, 27. 
[3] Eskiizmir, G., Hirçin, Z., Özyurt, B., & Ünlü, H. (2010). A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects. European Journal of Clinical Pharmacology, 67, 19-23. 
[4] Lötsch J, Geisslinger G, Hummel T. Sniffing out pharmacology: interactions of drugs with human olfaction. Trends Pharmacol Sci. 2012 Apr;33(4):193–9. 
[5] Zelano C, Jiang H, Zhou G, Arora N, Schuele S, Rosenow J, Gottfried JA. Nasal respiration entrains human limbic oscillations and modulates cognitive function. J Neurosci. 2016 Dec 7;36(49):12448–12467.
[6] Morrison RL, Fedgchin M, Singh J, Van Gerven J, Zuiker R, Lim KS, van der Ark P, Wajs E, Xi L, Zannikos P, Drevets WC. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl). 2018 Apr;235(4):1107-1119.
[7] Mizera L, Gossrau G, Hummel T, Haehner A. Effects of analgesics on olfactory function and the perception of intranasal trigeminal stimuli. Eur J Pain. 2017 Jan;21(1):92-100. 
[8] Mueller C, Renner B. A new procedure for the short screening of olfactory function using five items from the “Sniffin’ Sticks” identification test kit. Am J Rhinol. 2006;20:113–116.
[9] Solon-Júnior LJF, Vieira da Silva Neto L, Lima-Junior D, Costa YP, Klinger da Silva Oliveira J, Fiorese L, Fortes LS. "Encephalapp Stroop": Validity and reliability of a smartphone app to measure cognitive performance in physically active subjects. Appl Neuropsychol Adult. 2026 Jan-Feb;33(1):219-224.
[10] Kayserili G, Y?ld?r?m Z, Çilengiro?lu ÖV, Yener GG. A practical tool for the detection of limbic-type-memory deficit: 5-word test. Turk J Neurol. 2019.
[11] Hsu HC, Tan CD, Chang CW, Chu CW, Chiu YC, Pan CJ, Huang HM. Evaluation of nasal patency by visual analogue scale/nasal obstruction symptom evaluation questionnaires and anterior active rhinomanometry after septoplasty: a retrospective one-year follow-up cohort study. Clin Otolaryngol. 2017;42(1):53-59.
[12] Hummel T, Rothbauer C, Pauli E, Kobal G. Effects of the nasal decongestant oxymetazoline on human olfactory and intranasal trigeminal function in acute rhinitis. Eur J Clin Pharmacol. 1998;54(7):521-528.
[13] Eccles R, Eriksson M, Garreffa S, Chen SC. The nasal decongestant effect of xylometazoline in the common cold. Am J Rhinol. 2008;22(5):491-496.


IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications